Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 571 KB, PDF document
We investigated the humoral response to the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine in patients with myasthenia gravis on or off immunosuppressants and compared this to the response in healthy individuals. The SARS-CoV-2 IgG response and neutralizing capacity were measured in 83 patients (57 on immunosuppressants) and 332 healthy controls at baseline, three weeks, and two and six months after the vaccine. We found that the proportion of positive humoral response was lower in patients on immunosuppressants vs. controls at three weeks and two months (p ≤ 0.001), but not at six months post-vaccination (p = 0.379).
Original language | English |
---|---|
Article number | 578215 |
Journal | Journal of Neuroimmunology |
Volume | 384 |
Number of pages | 5 |
ISSN | 0165-5728 |
DOIs | |
Publication status | Published - 2023 |
Bibliographical note
Publisher Copyright:
© 2023 The Authors
- BNT162b2, COVID-19 vaccine, Humoral response, Myasthenia gravis
Research areas
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 374564945